Buprenorphine - Relmada Therapeutics

Drug Profile

Buprenorphine - Relmada Therapeutics

Alternative Names: Buprenorphine ER - Relmada Therapeutics; Buprenorphine extended release - Relmada Therapeutics; BuTab ER; REL-1028; TQ-1028

Latest Information Update: 18 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator TheraQuest Biosciences LLC
  • Developer Relmada Therapeutics
  • Class Cyclopropanes; Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action Nociceptin receptor agonists; Opioid delta receptor antagonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Opioid abuse; Pain

Most Recent Events

  • 10 Dec 2015 Positive top-line adverse events data from a phase I trial in healthy volunteers released by Relmada Therapeutics
  • 09 Dec 2015 Positive top-line pharmacokinetics data from a phase I trial in healthy volunteers released by Relmada Therapeutics
  • 21 Apr 2015 Phase-I clinical trials in Opioid abuse (In volunteers) in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top